<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24119825</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>68 Suppl 1</Volume><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>The enteroviruses: problems in need of treatments.</ArticleTitle><Pagination><StartPage>S108</StartPage><EndPage>S114</EndPage><MedlinePgn>S108-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2013.09.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(13)00287-9</ELocationID><Abstract><AbstractText>Specific antiviral therapy is currently not available for enterovirus (EV) infections. Poliomyelitis, EV 71 neurologic disease, and neonatal EV disease are three manifestations of EV infections that exemplify the importance of developing antivirals for EV infections. Despite tremendous strides in the effort to eradicate polio through vaccination, challenges remain, including the potential for transmission of neurovirulent vaccine-derived polioviruses which have genetically reverted from live-attenuated, oral poliovirus vaccine virus. EV 71 emerged in the late 1990 s in eastern Asia as a neurovirulent virus that causes large outbreaks of hand-foot-mouth disease, herpangina, and fever, and, in some children, meningitis, acute flaccid paralysis, and brainstem encephalitis complicated by pulmonary edema and cardiopulmonary collapse. EV infections in neonates can cause severe disease characterized by meningoencephalitis, myocarditis, pneumonitis, and/or hepatitis and coagulopathy. Prototypic agents for specific therapy of EV infections that act upon numerous potential viral targets exist. Three candidate compounds are currently in development: pleconaril (active against many EVs), V-073 (anti-poliovirus), and BTA-798 (active against many rhinoviruses and EVs). The three conditions described illustrate why development of antiviral medications for EV infections is a medically important need.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abzug</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine and Children's Hospital Colorado, Pediatric Infectious Diseases, Box B055, 13123 East 16th Avenue, Aurora, CO 80045, USA. Electronic address: mark.abzug@childrenscolorado.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Infect. 2016 Nov;73(5):512-515. doi: 10.1016/j.jinf.2016.08.007</RefSource><PMID Version="1">27546065</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010080" MajorTopicYN="N">Oxazoles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral therapy</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Neonatal</Keyword><Keyword MajorTopicYN="N">Poliomyelitis</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24119825</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2013.09.020</ArticleId><ArticleId IdType="pii">S0163-4453(13)00287-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>